During the past decade, Summit Research Network conducted 68 clinical trials. In the 10-year time frame, 68 clinical trials started and 74 clinical trials were completed, i.e. on average, 108.8% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 42 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Summit Research Network" #1 sponsor was "Pfizer" with 19 trials, followed by "Shire" with 14 trials sponsored, "Eli Lilly and Company" with 11 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored and "Cephalon" with 7 trials sponsored. Other sponsors include 84 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Summit Research Network" #1 collaborator was "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "National Institute on Aging (NIA)" with 2 trials as a collaborator, "Otsuka America Pharmaceutical" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "Worldwide Clinical Trials" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Summit Research Network" are "Major Depressive Disorder" (22 trials), "Alzheimer's Disease" (19 trials), "Alzheimer Disease" (16 trials), "Migraine" (7 trials) and "Obesity" (7 trials). Many other conditions were trialed in "Summit Research Network" in a lesser frequency.

Most popular intervention types in "Summit Research Network" are "Drug" (144 trials), "Other" (10 trials), "Biological" (4 trials), "Behavioral" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (70 trials), "placebo" (9 trials), "Crenezumab" (4 trials), "Escitalopram" (4 trials) and "Gantenerumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Summit Research Network" are 143 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Summit Research Network". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 105 completed trials in Summit Research Network, undefined suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Summit Research Network, 2 "Phase 1" clinical trials were conducted, 58 "Phase 2" clinical trials and 88 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 1 trials that are defined as “Not Applicable".